Close Menu

NEW YORK – With two US Food and Drug Administration-cleared platforms now on the market, digital pathology is poised to carve out a significant space in patient care.

Some clinicians question, though, whether the near-term benefits of digital pathology justify immediate investment in the technology, or if labs are better off waiting for more advanced platforms and applications that are expected from the technology further down the road.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.